# ClinicalTrials.gov record NCT02049034

> PeptideScanner retained ClinicalTrials.gov record NCT02049034 at 2026-07-30T18:37:14.684Z. Its registry update date was 2024-12-16, and PeptideScanner's reviewed identity mapping was lixisenatide.

- Evidence object: `story:clinicaltrials-gov-nct02049034-lixisenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-12-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02049034-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02049034-lixisenatide-v1.json
- Content SHA-256: `cba74faee0985ec1bd5bef7e29aa98271081e21488a42cb12381d4d558c7d357`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02049034 ([`ctg-observation-nct02049034-2024-12-16-9b9d70157c5b`](#source-ctg-observation-nct02049034-2024-12-16-9b9d70157c5b))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02049034 at 2026-07-30T18:37:14.684Z. Its registry update date was 2024-12-16, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02049034-2024-12-16-9b9d70157c5b`](#source-ctg-observation-nct02049034-2024-12-16-9b9d70157c5b))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02049034 at 2026-07-30T18:37:14.684Z. Its registry update date was 2024-12-16, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02049034-2024-12-16-9b9d70157c5b`](#source-ctg-observation-nct02049034-2024-12-16-9b9d70157c5b))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02049034-2024-12-16-9b9d70157c5b`](#source-ctg-observation-nct02049034-2024-12-16-9b9d70157c5b))

## Sources

<a id="source-ctg-observation-nct02049034-2024-12-16-9b9d70157c5b"></a>
- **ClinicalTrials.gov record NCT02049034 · retained source version 2024-12-16:9b9d70157c5bb521afbfc018957c1d0ce504d6a3867b0aca79f22426b20c713c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02049034) (`ctg-observation-nct02049034-2024-12-16-9b9d70157c5b`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02049034." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02049034-lixisenatide-v1.json SHA-256: cba74faee0985ec1bd5bef7e29aa98271081e21488a42cb12381d4d558c7d357.